Next Article in Journal
Prognostic Factors and Outcomes of Adult-Onset Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis of 34 Cases
Previous Article in Journal
Differential Diagnosis of Isolated Myeloid Sarcoma: A Case Report and Review of the Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 7
Issue 2
10.4081/hr.2015.5729
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy

by
Charles Yun
1,
Nikhil Mukhi
1,*,
Valerie Kremer
1,
Roman Shinder
2,
Vaibhav Verma
1 and
Olcay Batuman
1
1
Division of Hematology/Oncology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, New York, NY 11203, USA
2
Department of Ophthalmology, SUNY Downstate Medical Center, New York, NY 11203, USA
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2015, 7(2), 5729; https://doi.org/10.4081/hr.2015.5729
Submission received: 23 November 2014 / Revised: 8 March 2015 / Accepted: 16 April 2015 / Published: 9 June 2015

Abstract

Multiple myeloma (MM) is a neoplasm of plasma cells within the bone marrow. A major impact on improving survival in MM has been the use of the boronic acid-derived proteasome inhibitor bortezomib, a first-in-class selective inhibitor of the 26S proteasome. Ocular side effects of bortezomib are rare. In this report, we present 2 patients with active MM in whom persistent chalazia became a therapy-interfering complication of treatment with bortezomib. Both patients had relapsed ISS III B kappa light chain myeloma, and they were responding to treatment with bortezomib until chalazia−which caused intolerable discomfort−started. In both patients discontinuation of bortezomib was necessary for chalazia to heal, and restarting of bortezomib was associated with relapse of chalazia.
Keywords: chalazion; eye disease; bortezomib; multiple myeloma chalazion; eye disease; bortezomib; multiple myeloma

Share and Cite

MDPI and ACS Style

Yun, C.; Mukhi, N.; Kremer, V.; Shinder, R.; Verma, V.; Batuman, O. Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy. Hematol. Rep. 2015, 7, 5729. https://doi.org/10.4081/hr.2015.5729

AMA Style

Yun C, Mukhi N, Kremer V, Shinder R, Verma V, Batuman O. Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy. Hematology Reports. 2015; 7(2):5729. https://doi.org/10.4081/hr.2015.5729

Chicago/Turabian Style

Yun, Charles, Nikhil Mukhi, Valerie Kremer, Roman Shinder, Vaibhav Verma, and Olcay Batuman. 2015. "Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy" Hematology Reports 7, no. 2: 5729. https://doi.org/10.4081/hr.2015.5729

Article Metrics

Back to TopTop